Table 2.
Association of plasma TP42/40 with prodromal stages of AD
| β | 95% CI | P value | |
|---|---|---|---|
| CN vs. a-MCI | −1.958 | −3.882 to −0.034 | 0.046 |
| Association with FDG-PET | |||
| CN vs. a-MCIFDG(+) | −4.568 | −7.453 to −1.683 | 0.002 |
| a-MCIFDG(-) vs. a-MCIFDG(+) | −3.283 | −5.862 to −0.704 | 0.013 |
| Association with progression to AD | |||
| CN vs. a-MCIsta | −0.932 | −3.080 to 1.216 | 0.395 |
| CN vs. a-MCIprog | −3.212 | −5.752 to −0.672 | 0.013 |
| a-MCIsta vs. a-MCIprog | −2.828 | −5.160 to −0.496 | 0.017 |
Comparison of TP42/40 levels between groups was carried out using generalized linear models adjusted for age, APOE genotype and education level. TP42/40 levels were compared between CN and a-MCI individuals, and between the subclassification of a-MCI subjects based on FDG-PET at baseline. β, coefficient of GLM regression; 95% CI, 95% confidence interval; CN, cognitively normal individuals; a-MCI, amnestic mild cognitive impairment; a-MCIFDG(-), a-MCI subjects with low probability of AD according to a FDG-PET neurodegeneration pattern; a-MCIFDG(+), a-MCI subjects with high probability of AD according to a FDG-PET neurodegeneration pattern. a-MCIsta, a-MCI stables at the end of the follow-up; a-MCIprog, a-MCI at baseline who progressed to AD dementia during the study period.